Literature DB >> 8778026

Cytokine expression by high-density human lymphocytes.

W A Sewell1, M F Berger, L J Skipsey, M A Cooley, H S Warren.   

Abstract

T lymphocytes spend much of the time as small non-cycling cells. To determine the pattern of cytokine expression in such resting cells, they were purified from human peripheral blood mononuclear cells (PBMC) on the basis of high buoyant density. The cells were stimulated and cytokine mRNA expression was assessed by reverse transcription-polymerase chain reaction (RT-PCR). Expression of interleukin-2 (IL-2), IL-3 and interferon-gamma (IFN-gamma) was similar in high-density lymphocytes and in unfractionated PBMC. In contrast, the high-density lymphocytes expressed less IL-4 than PBMC, and little or no IL-5. Because a substantial minority of the high-density lymphocytes was CD45RO+, the presence of this marker was not an indicator of the ability to express IL-4 and IL-5. In the high-density lymphocytes, IFN-gamma expression was confined to the CD45RO+ fraction, whereas IL-2 was expressed by both CD45RO+ and CD45RO- subsets. To assess whether high-density lymphocytes could give rise to cells with a broader range of inducible cytokine expression, they were activated and then restimulated between 10 and 22 days of culture. Cells derived from both the CD45RO+ and CD45RO- fractions of high-density lymphocytes expressed IL-5 after restimulation. Thus the high-density lymphocyte population has the potential to acquire a broader range of inducible cytokine expression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8778026      PMCID: PMC1384109          DOI: 10.1046/j.1365-2567.1996.501572.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  29 in total

1.  Frequencies of interleukin-5 mRNA-producing cells in healthy individuals and in immunoglobulin-deficient patients, measured by in situ hybridization.

Authors:  C I Smith; G Möller; E Severinson; L Hammarström
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

2.  Kinetic study of T lymphocytes after sensitization against soluble antigen. I. Separation on density gradients.

Authors:  H G Durkin; B H Waksman
Journal:  J Immunol       Date:  1975-07       Impact factor: 5.422

3.  Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells.

Authors:  A N Akbar; L Terry; A Timms; P C Beverley; G Janossy
Journal:  J Immunol       Date:  1988-04-01       Impact factor: 5.422

4.  In vivo estimates of division and death rates of human T lymphocytes.

Authors:  A R Mclean; C A Michie
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

Review 5.  Lymphocyte life-span and memory.

Authors:  J Sprent; D F Tough
Journal:  Science       Date:  1994-09-02       Impact factor: 47.728

6.  The interleukin-2 T-cell system: a new cell growth model.

Authors:  D A Cantrell; K A Smith
Journal:  Science       Date:  1984-06-22       Impact factor: 47.728

7.  Heterogeneity in the activation requirements of T cells stimulated by phytohaemagglutinin.

Authors:  H S Warren; A Bezos
Journal:  Immunology       Date:  1987-06       Impact factor: 7.397

8.  Differential expression and regulation of cytokine mRNAs in normal human CD45R T cell subsets.

Authors:  I Beckman; K Shepherd; K Dimopoulos; M Ahern; F Firgaira; J Bradley
Journal:  Cytokine       Date:  1994-03       Impact factor: 3.861

9.  Characterization of T helper 1 and 2 cell subsets in normal mice. Helper T cells responsible for IL-4 and IL-5 production are present as precursors that require priming before they develop into lymphokine-secreting cells.

Authors:  S L Swain; D T McKenzie; A D Weinberg; W Hancock
Journal:  J Immunol       Date:  1988-11-15       Impact factor: 5.422

10.  Two subsets of human CD4+ T helper cells differing in kinetics and capacities to produce interleukin 2 and interferon-gamma can be defined by the Leu-18 and UCHL1 monoclonal antibodies.

Authors:  M Dohlsten; G Hedlund; H O Sjögren; R Carlsson
Journal:  Eur J Immunol       Date:  1988-08       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.